



MINISTÉRIO DA SAÚDE
Assessoria Especial de Assuntos Internacionais

152nd Session of the Executive Board

30 January - 07 February 2023

Item 9 - Draft Global Strategy on Infection Prevention and Control

- Previous outbreaks and the COVID-19 pandemic have demonstrated the gaps in infection prevention and control programmes around the world. Brazil urges the importance of an action plan and monitoring framework with a solid architecture for health emergencies, especially with the increasing endemic burden of healthcare-associated infections.
- Brazil has taken important steps to implement the Resolution on infection prevention control (WHA.75.13), on national facilities, in line with the recommended core components of the programme. Moreover, Brazil is engaged in efforts to expand productive capacities, as well as research, development and innovation capabilities, at regional and local levels.
- Brazil is aligned with the global strategy on infection and prevention control, following its objectives of “Prevent, Act and Coordinate” to strengthen the foundations and implementation of future programmes for universal health coverage and emergencies.



MINISTÉRIO DA SAÚDE

Assessoria Especial de Assuntos Internacionais

- Brazil is committed to mobilise resources to sustain the infection prevention and control programmes, especially health priorities, emphasising neglected populations and diseases, such as leprosy, schistosomiasis, onchocerciasis and filariasis.
- Brazil is organising a big data approach integrating social, economic and environmental determinants of health with genomic data for an advanced system of surveillance.
- Brazil understands that discussions around AMR must be firmly defined by scientific studies and risk assessments. We suggest that this discussion integrate different sectors and areas, with WHO working within its mandate in order to improve health for all.
- Brazil is committed to promote access to quality and affordable essential antimicrobials, since equitable and affordable access remains the first step to ensuring prudent use, to bolster local production and innovation for development of new antimicrobials.